Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Review Which Crypto Strategies Are Low Risk, focusing on capital preservation, diversification, and disciplined rebalancing.
27,978 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A cold email from a Dallas founder led Mark Cuban to back a nascent space company with $500,000. Today, Relativity Sp...
A 62-year-old considers retiring to Palm Coast on a $3,000 monthly budget, weighing housing costs, insurance, and uti...
Chevron's CEO warns that jet fuel shortages may push aviation costs higher as carriers trim schedules and consumers f...
A wave of real income is emerging in select small-cap stocks, not in the obvious dividend leaders. Analysts say real ...
Prices stay higher than a few years ago, eroding cash savings. A trio of ETFs—GLD, VTIP, and DBC—are positioned to he...
As streaming shifts accelerate, FuboTV's 2026 earnings outlook hinges on subscriber growth, ad revenue, and content c...
As Sprinklr (CXM) gears up for 2027 earnings, investors will scrutinize revenue growth, margins, and customer stickin...
Nvidia stands at a crossroads: rising Chinese demand for AI GPUs could lift sales, but policy risks and fierce compet...
Kennametal’s Q3 2026 results shed light on the company’s path through a challenging manufacturing environment. This a...
Three active AI-focused ETFs are pulling ahead as corporate AI investments surge. This report explains why after mont...
As SpaceX prepares to debut on the public market, analysts clash over whether the company is fairly valued amid volat...